Provider Briefing: Acthar Gel Access in 2026

Acthar Gel (repository corticotropin injection) occupies a unique niche in the treatment of complex autoimmune and inflammatory conditions — and a uniquely frustrating position in the supply chain. For providers prescribing this medication, navigating availability, insurance requirements, and patient access has become as much a part of the treatment plan as the clinical decision to prescribe it.

This guide provides an updated overview of the Acthar Gel landscape in 2026, with practical information for neurologists, rheumatologists, nephrologists, pulmonologists, ophthalmologists, and other specialists who prescribe this medication.

Supply Timeline and Current Status

Historical Context

Acthar Gel has been on the market since the 1950s and is manufactured exclusively by Mallinckrodt Pharmaceuticals (now operating as a reorganized entity following Chapter 11 bankruptcy in 2020, with emergence in June 2022).

Key milestones affecting supply:

• 2020: Mallinckrodt files Chapter 11 bankruptcy, creating supply uncertainty
• 2021: ANI Pharmaceuticals receives FDA approval for Purified Cortrophin Gel, introducing the first competitor in the ACTH class
• 2022: Mallinckrodt emerges from bankruptcy; production stabilizes
• 2024: Launch of the SelfJect auto-injector device for subcutaneous administration; 3% list price increase in January
• 2025-2026: Supply generally stable at the manufacturing level, but access challenges persist at the patient level

Current FDA Status

As of early 2026, Acthar Gel is not listed on the FDA Drug Shortage database. However, the specialty pharmacy distribution model and single-manufacturer supply chain mean that localized access challenges continue to affect patients across the country.

Prescribing Implications

FDA-Approved Indications

Acthar Gel carries FDA approval for a broad range of conditions across multiple specialties:

• Neurology: Infantile spasms (monotherapy, children <2), acute MS exacerbations
• Rheumatology: RA, juvenile RA, psoriatic arthritis, ankylosing spondylitis, SLE, dermatomyositis/polymyositis
• Nephrology: Nephrotic syndrome (idiopathic or lupus-related)
• Pulmonology: Symptomatic sarcoidosis
• Ophthalmology: Keratitis, iritis, uveitis, optic neuritis, chorioretinitis
• Dermatology: Severe erythema multiforme, Stevens-Johnson syndrome
• Allergology: Serum sickness

Step Therapy and Documentation Requirements

Nearly all payers require step therapy documentation before approving Acthar Gel. Prescribers should be prepared to document:

• Diagnosis confirmation with supporting labs/imaging
• Prior treatment trials with corticosteroids (typically IV methylprednisolone or oral prednisone) and documented inadequate response or intolerance
• Rationale for Acthar Gel over continued corticosteroid therapy
• Treatment plan including expected duration and monitoring parameters

Proactively submitting comprehensive documentation with the initial prior authorization request reduces denial rates and speeds approval.

The Availability Picture

Distribution Model

Acthar Gel is distributed exclusively through specialty pharmacies. Key points for provider practices:

• Patients cannot fill prescriptions at retail pharmacies
• Specialty pharmacies may have varying inventory levels
• Delivery timelines typically range from 2-7 business days after authorization
• Some specialty pharmacies have dedicated Acthar Gel coordinators

The SelfJect Device

The SelfJect auto-injector, available in 40-unit and 80-unit pre-filled single-dose configurations, simplifies subcutaneous self-administration for adult patients. Key clinical considerations:

• For subcutaneous use only (not IM) — cannot be used for infantile spasms
• Available for adult patients (18+) only
• May improve adherence by reducing injection complexity
• Dosing limited to 40 or 80 units per injection; use the multi-dose vial for other dose levels

Cost and Access Landscape

Current Pricing

• WAC: ~$9,061/mL
• 5 mL multi-dose vial: ~$45,600
• SelfJect 4-pack (80 units/1 mL each): ~$36,500
• SelfJect 4-pack (40 units/0.5 mL each): ~$18,200

Insurance Coverage

Acthar Gel is covered by most commercial plans and Medicare (Part B for physician-administered, Part D for self-administered). Coverage almost universally requires:

• Prior authorization
• Step therapy documentation
• Periodic re-authorization (typically every 3-6 months)

Patient Financial Support

Mallinckrodt offers several support programs that practices should be aware of:

• Commercial Copay Program: Eligible commercially insured patients pay as little as $0, with up to $15,000/year in savings
• Patient Assistance Program (PAP): Free medication for uninsured/underinsured patients at or below 700% FPL
• Acthar Patient Support: Dedicated team assisting with insurance navigation, prior authorization, and specialty pharmacy coordination (1-888-435-2284)
• Patient Access Network Foundation (PAN): Copay assistance for insured patients between 400-500% FPL

Tools and Resources for Providers

Medfinder for Providers

Medfinder helps providers and their staff locate specialty pharmacies with current Acthar Gel availability. Rather than calling multiple pharmacies, your team can use Medfinder to quickly identify where to send prescriptions for the fastest fulfillment.

Acthar HCP Resources

Mallinckrodt provides provider-specific resources at actharhcp.com, including:

• Prior authorization support and sample letters
• Clinical data summaries by indication
• Dosing guides and administration resources
• Patient education materials

Practice Workflow Tips

• Designate a staff member to manage specialty medication authorizations
• Submit prior authorization concurrently with the prescription — don't wait for pharmacy-triggered requests
• Keep template documentation for each indication to streamline PA submissions
• Familiarize your team with the peer-to-peer review process for denials
• Consider enrolling patients in Acthar Patient Support at the time of prescribing

Looking Ahead

The ACTH therapy landscape is evolving slowly but meaningfully. With Purified Cortrophin Gel providing a competitive alternative (at ~23% lower cost), and ongoing research into the melanocortin receptor pathway, providers may see expanded options in the coming years. For now, Acthar Gel remains the only FDA-approved ACTH therapy for infantile spasms and continues to be a critical treatment for patients who have failed conventional corticosteroid therapy.

Staying informed about supply status, proactively managing prior authorization, and leveraging tools like Medfinder for providers can meaningfully improve your patients' access to this important medication.

Final Thoughts

Prescribing Acthar Gel in 2026 requires clinical expertise and logistical preparation in equal measure. The medication itself remains effective for its approved indications, but the single-manufacturer model, specialty distribution requirements, and payer gatekeeping demand active management from the prescribing team.

For patient-facing information to share with your patients, see our articles on why Acthar Gel is hard to find, how to find it in stock, and how to save money on Acthar Gel. For a companion provider guide focused on day-to-day workflow, read how to help your patients find Acthar Gel in stock.